STOCK TITAN

Kalvista Pharm - KALV STOCK NEWS

Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.

KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.

Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.

Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.

Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) has submitted a New Drug Application (NDA) to the FDA for sebetralstat, an oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE) in patients aged 12 and older. The NDA is based on successful phase 3 trial results showing rapid symptom relief, with sebetralstat significantly outperforming placebo. If approved, sebetralstat would be the first oral on-demand HAE treatment. The FDA's review decision is expected in September 2024. KalVista also plans to submit marketing applications globally and initiate a pediatric trial in Q3 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
-
Rhea-AI Summary

KalVista Pharmaceuticals presented data from the US subgroup of the phase 3 KONFIDENT trial and real-world claims at the Eastern Allergy Conference 2024, and the Japanese subgroup at the Japanese Dermatological Association 2024. The US subgroup showed a median time to treatment of 38 minutes and symptom relief beginning at 1.3 hours, comparing favorably with overall trial results. Despite increased long-term prophylaxis use in the US, on-demand treatment prescriptions remain steady, with significant non-prescription healthcare costs. Japanese trial results were consistent with overall data, and sebetralstat was well tolerated with no serious adverse events. Real-world data also highlighted that HAE attacks impact quality of life and work productivity similarly for both prophylaxis and on-demand treatment patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) announced the issuance of inducement stock options to a newly-hired employee on June 3, 2024. The compensation committee of the board of directors granted options to purchase 7,000 shares of KalVista common stock. These options are part of the company's Inducement Equity Incentive Plan, granted under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $12.11 per share, which matched the closing price on the grant date. One-fourth of the options vest after one year, with the remaining shares vesting monthly over the next three years, contingent on the employee's continued service. Each option has a 10-year term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
Rhea-AI Summary

KalVista Pharmaceuticals presented new data on hereditary angioedema (HAE) at the EAACI Congress 2024, spotlighting significant unmet needs despite current treatments.

Key findings include the challenges of injectable on-demand therapies, with 50% of US patients experiencing untreated HAE attacks worsening in severity. Common reasons for not treating include saving medication for severe attacks and avoiding needle pain.

UK data shows 63% of patients perceive their treatment as 'early,' yet only 14% treat within one hour. Anxiety about using injectable therapies is also a major concern.

Patients who treat early recover faster and feel less anxious. There's strong patient preference for oral treatments, anticipating higher usage and less anxiety.

Physicians report significant issues with non-androgen long-term prophylaxis, including moderate to very severe attacks and high treatment burdens. KalVista highlighted the potential of oral sebetralstat to address these challenges based on positive Phase 3 KONFIDENT results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals announced that data from the phase 3 KONFIDENT trial of sebetralstat, an oral treatment for hereditary angioedema (HAE), was published in the New England Journal of Medicine and presented at the European Academy of Allergy and Clinical Immunology Congress 2024.

The trial met its primary and secondary endpoints, with a median symptom relief time of 1.61 hours for 300 mg and 1.79 hours for 600 mg doses, compared to 6.72 hours for placebo. The safety profile was comparable to placebo, with low adverse event rates.

In the KONFIDENT-S open-label trial, sebetralstat showed a median treatment time of 9 minutes and a median symptom relief time of 1.8 hours, with consistent efficacy across various attack severities and locations.

KalVista plans to submit a new drug application to the US FDA in June 2024, and later in the EU and Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
-
Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of ten abstracts for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 in Valencia, Spain, from May 31 to June 3. Highlights include late-breaking presentations on the phase 3 KONFIDENT and KONFIDENT-S trials of sebetralstat, an oral treatment for hereditary angioedema (HAE), and multiple real-world data presentations addressing delays in injectable on-demand treatments for HAE. Key sessions are scheduled throughout the event, including oral abstracts, poster presentations, and symposiums focusing on various aspects of HAE treatment and patient experiences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
Rhea-AI Summary

KalVista Pharmaceuticals, a clinical-stage pharmaceutical company focusing on oral, small molecule protease inhibitors, announced participation in two upcoming investor conferences. The management will join a virtual fireside chat at the Stifel 2024 Tailoring Genes: Genetic Medicines Forum on May 28, 2024, at 12:50 p.m. ET, and the Jefferies Global Healthcare Conference in New York on June 5, 2024, at 3:00 p.m. ET. The presentations will be webcasted live, with an audio archive available on the company's website for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
conferences
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) granted ten newly-hired employees inducement options to purchase 94,000 shares of common stock on May 1, 2024. The options have an exercise price of $12.18 per share and vest over a four-year period. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its strategic plans for fiscal year 2025, focusing on sebetralstat, an oral therapy for hereditary angioedema. The company aims to finalize regulatory filings in the US, EU, UK, and Japan for potential commercial launches in 2025-2026. KalVista plans to engage commercial partners, extend the product lifecycle, and reduce spending on non-core activities to achieve positive cash flow within a few years of commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) appoints William C. Fairey, former Chief Commercial Officer at MyoKardia, to its Board of Directors. Mr. Fairey brings over 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry. His expertise in rare diseases and product launches will support KalVista's focus on the FDA submission, potential approval, and commercial launch of sebetralstat, a treatment for hereditary angioedema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
management
Kalvista Pharm

Nasdaq:KALV

KALV Rankings

KALV Stock Data

571.23M
44.06M
1.36%
113.48%
11.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE